ARVN stock icon

Arvinas
ARVN

$31.19
4.71%

Market Cap: 2.13B

 

About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Employees: 445

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 16 analysts
0
News positive %
of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

64% more call options, than puts

Call options by funds: $10.3M | Put options by funds: $6.32M

38% more funds holding in top 10

Funds holding in top 10: 8 [Q4 2023] → 11 (+3) [Q1 2024]

29% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 28

22% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 67

4% more funds holding

Funds holding: 209 [Q4 2023] → 217 (+8) [Q1 2024]

5% more capital invested

Capital invested by funds: $2.66B [Q4 2023] → $2.78B (+$123M) [Q1 2024]

18.41% less ownership

Funds ownership: 117.58% [Q4 2023] → 99.16% (-18.41%) [Q1 2024]

Research analyst outlook

16 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$52
67%
upside
Avg. target
$72
131%
upside
High target
$90
189%
upside

16 analyst ratings

14 positive
88%
neutral
13%
negative
0%
HC Wainwright & Co.
Andrew Fein
179%upside
$87
Buy
Reiterated
17 May 2024
Wells Fargo
Derek Archila
92%upside
$60
Overweight
Maintained
9 May 2024
Wedbush
Robert Driscoll
67%upside
$52
Outperform
Reiterated
8 May 2024
Stifel
Bradley Canino
118%upside
$68
Buy
Maintained
8 May 2024
HC Wainwright & Co.
Andrew Fein
179%upside
$87
Buy
Reiterated
8 May 2024

Financial journalist opinion

Based on 4 articles about ARVN published over the past 30 days